큐라티스
Financials
Valuation Metrics
큐라티스's Market Cap is ₩295B. At end of 2025 it was ₩1457B. Ranked #2075 of 2,436 in KR market (top 85%), #1321 of 1,649 on KOSDAQ (top 80%), #217 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 29.50B KRW | KR#2,075/2,436 Sec#217/234 |
| Revenue | 1.26B KRW | KR#2,390/2,436 Sec#218/234 |
| Net Income | -30.97B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 61.30B KRW | KR#2,071/2,436 Sec#181/234 |
| Net Assets | 50.30B KRW | KR#1,873/2,436 Sec#162/234 |
| Employees | 72 | KR#1,841/2,436 Sec#157/234 |
| Value | ||
| P/B | 0.59x | KR#963/2,436 Sec#48/234 |
| P/S | 23.49x | KR#2,342/2,436 Sec#187/234 |
| FCF Yield | -51.79% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -61.57% | KR#2,295/2,436 Sec#206/234 |
| ROA | -50.53% | KR#2,357/2,436 Sec#219/234 |
| Op. Margin | -802.99% | KR#2,385/2,436 Sec#214/234 |
| Revenue Growth | -99.22% | KR#2,345/2,436 Sec#212/234 |
| Financial Health | ||
| Debt Ratio | 121.86% | KR#697/2,436 Sec#85/234 |
| Total Debt | 9.43B KRW | KR#1,643/2,436 Sec#148/234 |
| FCF | -15.28B KRW | KR#1,834/2,436 Sec#168/234 |
| Cash | 14.42B KRW | KR#1,446/2,436 Sec#108/234 |
| Current Ratio | 1.49x | KR#1,314/2,436 Sec#143/234 |
| Performance | ||
| 1Y Return | -72.08% | KR#2,360/2,436 Sec#225/234 |
| 1M Return | -14.81% | KR#2,019/2,436 Sec#199/234 |
| From 52W High | -82.27% | KR#2,374/2,436 Sec#228/234 |
| 1Y MDD | -84.62% | KR#2,368/2,436 Sec#227/234 |
| Trading | ||
| Volume | 65,995 shares | KR#1,186/2,436 Sec#117/234 |
| Foreign Own. | 3.99% | KR#899/2,436 Sec#87/234 |
| Per Share | ||
| EPS | -3,492 KRW | KR—/2,436 Sec—/234 |
| BPS | 3,922 KRW | KR#1,626/2,436 Sec#125/234 |
Company Info
Established in 2016, this company possesses vaccine development platform technology and was listed on KOSDAQ in 2023. It is developing preventive vaccines for adult and adolescent tuberculosis, schistosomiasis, and next-generation mRNA COVID-19, operating manufacturing facilities and research laboratories that meet cGMP, EU-GMP, and KGMP standards. Utilizing its vaccine development platform technology, the company conducts the entire new drug development process and offers services and consulting to bio new drug development clients. Curatis, established in 2016, is headquartered in Chungcheongbuk Province, Cheongju City.